Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genmab ( (GMAB) ) has shared an announcement.
On December 12, 2025, Genmab A/S announced the successful completion of its tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share, marking a significant step in its strategy to become a global biotechnology leader. This acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio, and is expected to be accretive to the company’s EBITDA by the end of 2029, with potential multi-billion-dollar annual revenue thereafter.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has a strong presence across North America, Europe, and Asia Pacific. The company is known for its next-generation antibody technology platforms and aims to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 2,102,069
Technical Sentiment Signal: Buy
Current Market Cap: $19.27B
For detailed information about GMAB stock, go to TipRanks’ Stock Analysis page.